Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Single-cycle melphalan 200 mg/m and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, ran...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 37; číslo 7; s. 589
Hlavní autoři:	Stadtmauer, Edward A, Pasquini, Marcelo C, Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M, Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H, Shah, Nina, Vesole, David H, Vij, Ravi, Vogl, Dan T, Giralt, Sergio, Somlo, George, Krishnan, Amrita
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.03.2019
Témata:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib - administration & dosage Bortezomib - adverse effects Consolidation Chemotherapy Dexamethasone - administration & dosage Dexamethasone - adverse effects Disease Progression Female Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - mortality Humans Lenalidomide - administration & dosage Lenalidomide - adverse effects Maintenance Chemotherapy Male Melphalan - administration & dosage Middle Aged Multiple Myeloma - mortality Multiple Myeloma - pathology Multiple Myeloma - therapy Myeloablative Agonists - administration & dosage Progression-Free Survival Prospective Studies Remission Induction Reoperation Time Factors Transplantation, Autologous United States Young Adult United States
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!